Current reimbursement models in general do not accommodate many of the unique factors common among gene and cell therapies. In this second article of a three-part series, CRA’s Walter Colasante, Pascale Diesel, and Lev Gerlovin discuss the challenges to demonstrating value and addressing affordability and discuss options for payment models.
The authors wish to acknowledge the contributions of Stephanie Donahue and Michael Krepps to this article.
Click here to read the article.
Takeaways from roundtable discussion on Medical Affairs challenges at MAPS 2023 Global Annual Meeting
In spring 2023, CRA’s Life Sciences Practice held a roundtable discussion with Medical Affairs leaders to better understand obstacles prohibiting their teams...